I have three data points across nine months, which I hope is enough to see a trend.
This is presented as though it settles something, and I am not convinced it does.
I have two documents that appear to disagree, which is what prompted this.
Which parts of this are informative and which are decoration?
Answering this needs the eGFR entry criteria of the trial you are quoting, because renal trials enrol by kidney function and the results do not transfer across strata.
Slope-based endpoints — the rate of eGFR decline in millilitres per minute per year — are increasingly used because they need fewer participants than event counts. They are legitimate and they are not events.
| Quantity | Value | Derivation |
|---|---|---|
| Control-arm event rate | 8.0 % | From the trial table, not the abstract |
| Hazard ratio | 0.80 | Reported |
| Treated event rate | 6.4 % | 8.0 × 0.80 |
| Absolute risk reduction | 1.6 pp | 8.0 − 6.4 |
| Number needed to treat | 63 | 1 ÷ 0.016 |
| Relative risk reduction | 20 % | 1 − 0.80 |
The last two rows describe the same finding. Only one of them is used in headlines.
Stated carefully, renal risk in practice comes from volume depletion: persistent vomiting or diarrhoea during dose escalation reduces renal perfusion, and acute kidney injury reported in this class clusters around exactly those episodes.
FLOW is the dedicated kidney-outcome trial in this class and is the appropriate citation for hard renal endpoints rather than a subgroup of a cardiovascular trial.
The caveat is that kidney function is exactly the sort of thing that should not be managed from a forum. This is background, not guidance.
If gastrointestinal effects are severe enough to affect fluid intake, that is the renal risk worth attending to.
edited 18 Jul 2025 by Dr_Colm_Fitzhenry — added the citation requested in comments
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsStated carefully, the distinction that matters is between albuminuria — a surrogate — and hard kidney endpoints such as sustained eGFR decline, kidney failure or renal death. Both move, and they do not carry the same weight.
FLOW randomised people with type 2 diabetes and chronic kidney disease to semaglutide and reported roughly a twenty-four per cent reduction in the primary kidney composite, which combined kidney failure, sustained large eGFR decline and death from kidney or cardiovascular causes.
Specifically, proteinuria reduction appears early, within months; the divergence in hard endpoints takes years. A trial short enough to see the first is too short to see the second.
Earlier renal findings came as secondary composites within cardiovascular outcome trials and were dominated by the albuminuria component, which is why the dedicated trial mattered.
A surrogate that moves is encouraging. A surrogate that moves is also how several drug classes in other fields were shown to be useless.
The early eGFR dip is expected. The long-run slope is the outcome. Do not confuse the two.
Answer first: the renal signal in this class is real and was demonstrated most clearly in a trial designed for it rather than as a secondary endpoint of a cardiovascular trial.
Trials in this area enrol by eGFR band, commonly from twenty-five or thirty upwards. A result from a cohort with eGFR above sixty says little about someone at thirty-five.
Combination with other agents acting on the same haemodynamics changes the picture, and that interaction is a clinical question rather than a pharmacological curiosity.
Research-use compounds are not approved for human use, and unverified content makes any dose-related renal reasoning unfounded from the start.
Cite FLOW for hard kidney endpoints, not a cardiovascular trial subgroup.
The honest answer is that the class slows progression in diabetic kidney disease and that no trial has shown it reverses established damage.
The initial eGFR dip is on the order of one to three millilitres per minute per 1.73 square metres and recovers. Reading it as harm and stopping is the error the pattern is designed to catch you with.
Regulatory acceptance of eGFR slope as an endpoint rests on published meta-analyses linking slope to subsequent kidney failure across many trials and drug classes.
Nothing here is medical advice, and anyone with existing kidney disease has a genuinely different risk calculus that needs a clinician.
Albuminuria is the fast signal and the composite is the answer.
The short version: reduced progression of kidney disease in the population studied, on a hard composite, with an effect size in the same region as the cardiovascular one.
Urinary albumin-to-creatinine ratio falls substantially in this class, often by thirty per cent or more. It is a good surrogate and it is still a surrogate; the reason FLOW mattered is that it measured the thing itself.
The caveat is the population. Trial participants were screened, monitored and supported; the effect size in an unmonitored setting is not the trial effect size, and it is not obvious in which direction the difference runs.
Quote the eGFR entry band with any renal result, or the result does not travel.
edited 16 Sept 2025 by Dr_Sara_Kuusela — removed a claim I could not source
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.